Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

Before losing her job at USAID, Katomski’s research division was considering trials for lenacapavir, the 2024 “breakthrough” drug. “All of that’s just been cut off,” she says.

A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s while ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...